Copy to clipboard 
Forma Medical is pursuing a sharpened strategic focus on OptimalMTP, a procedure that enables minimally invasive plating of first metatarsophalangeal (MTP) joint fusion. Further, the company was issued a key methods patent.
The commercial growth of OptimalMTP has accelerated since its launch, with demonstrated clinical success in over 650 patients. Building on this clinical and commercial momentum, Forma Medical is prioritizing its resources to drive the continued growth of the OptimalMTP procedure. The company believes this focus will accelerate surgeon adoption, deepen clinical evidence, and establish OptimalMTP as the category-defining solution for MTP fusion.
Forma Medical also announced the issuance of U.S. Patent No. 12,521,157. The newly issued patent secures broad method claims covering minimally invasive joint fixation with a low-profile plating construct delivered through limited incisions, protecting critical procedural innovations. These methods enable surgeons to apply the gold-standard plate-and-screw construct using minimally invasive techniques, aligning trusted surgical biomechanics with modern patient expectations.
Further, Forma has appointed Aaron Smith to its Board of Directors. Mr. Smith most recently served as CEO of Artelon, which was acquired by Stryker.
“This patent protects the technology that allows surgeons to achieve both minimally invasive procedures and decades of proven biomechanics: exactly what our mission is about,” said Andrew C. Davison, CEO of Forma Medical. “OptimalMTP™ brings these two critical goals together, and the strong clinical adoption shows how much this capability is needed. With a sharpened strategic focus and the addition of Aaron Smith to our Board, Forma is well positioned to lead the evolution in MTP fusion.”
Source: Forma Medical
Forma Medical is pursuing a sharpened strategic focus on OptimalMTP, a procedure that enables minimally invasive plating of first metatarsophalangeal (MTP) joint fusion. Further, the company was issued a key methods patent.
The commercial growth of OptimalMTP has accelerated since its launch, with demonstrated clinical success in over 650...
Forma Medical is pursuing a sharpened strategic focus on OptimalMTP, a procedure that enables minimally invasive plating of first metatarsophalangeal (MTP) joint fusion. Further, the company was issued a key methods patent.
The commercial growth of OptimalMTP has accelerated since its launch, with demonstrated clinical success in over 650 patients. Building on this clinical and commercial momentum, Forma Medical is prioritizing its resources to drive the continued growth of the OptimalMTP procedure. The company believes this focus will accelerate surgeon adoption, deepen clinical evidence, and establish OptimalMTP as the category-defining solution for MTP fusion.
Forma Medical also announced the issuance of U.S. Patent No. 12,521,157. The newly issued patent secures broad method claims covering minimally invasive joint fixation with a low-profile plating construct delivered through limited incisions, protecting critical procedural innovations. These methods enable surgeons to apply the gold-standard plate-and-screw construct using minimally invasive techniques, aligning trusted surgical biomechanics with modern patient expectations.
Further, Forma has appointed Aaron Smith to its Board of Directors. Mr. Smith most recently served as CEO of Artelon, which was acquired by Stryker.
“This patent protects the technology that allows surgeons to achieve both minimally invasive procedures and decades of proven biomechanics: exactly what our mission is about,” said Andrew C. Davison, CEO of Forma Medical. “OptimalMTP™ brings these two critical goals together, and the strong clinical adoption shows how much this capability is needed. With a sharpened strategic focus and the addition of Aaron Smith to our Board, Forma is well positioned to lead the evolution in MTP fusion.”
Source: Forma Medical
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
